Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Abstral Articles

News briefs from Genzyme, Sagent, Orchid and Kyowa Hakko

14 November 2012

Orexo to explore strategic alternatives for commercialization in the USA

7 October 2012

Orexo and ProStrakan reconfigure rights to Abstral

4 June 2012

Orexo licenses Abstral to Invida for in Asia Pacific: GlaxoSmithKline gets rights to bilastine in Spain and Poland

17 January 2011

US FDA finally approves ProStrakan opioid analgesic Abstral

10 January 2011

ProStrakan faces Abstral production shortage and FDA hold-up of Sancuso, as CEO resigns

8 September 2010

Painful wait for ProStrakan on Abstral’s US approval

18 August 2010

US FDA delays ProStrakan’s Abstral approval

3 June 2010

Showing 1-8 of 8 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS